Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.

Literature DB >> 26992943

Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.

Nicole Kucine¹, Aaron D Viny², Raajit Rampal², Michael Berger³, Nicholas Socci³, Agnes Viale³, James B Bussel⁴, Ross L Levine², Franck Rapaport⁵.

Abstract

Entities: Disease Species

Keywords: chronic myeloproliferative disorders; cytogenetics and molecular genetics; pediatric

Mesh：

Year: 2016 PMID： 26992943 PMCID： PMC5013957 DOI： 10.3324/haematol.2016.142935

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

Review 1. Primary thrombocytosis in children.

Authors: Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal: Haematologica Date: 2014-04 Impact factor: 9.941

Review 2. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors: A Tefferi; J W Vardiman
Journal: Leukemia Date: 2007-09-20 Impact factor: 11.528

3. Androgen-responsive gene database: integrated knowledge on androgen-responsive genes.

Authors: Mei Jiang; Yunsheng Ma; Congcong Chen; Xuping Fu; Shu Yang; Xia Li; Guohua Yu; Yumin Mao; Yi Xie; Yao Li
Journal: Mol Endocrinol Date: 2009-09-17

4. The molecular landscape of childhood myeloproliferative neoplasms.

Authors: Stephen E Langabeer; Karl Haslam; Corrina McMahon
Journal: Leuk Res Date: 2014-06-12 Impact factor: 3.156

5. CALR mutations are rare in childhood essential thrombocythemia.

Authors: Stephen E Langabeer; Karl Haslam; Corrina McMahon
Journal: Pediatr Blood Cancer Date: 2014-02-13 Impact factor: 3.167

6. The role of different genetic subtypes of CEBPA mutated AML.

Authors: A Fasan; C Haferlach; T Alpermann; S Jeromin; V Grossmann; C Eder; S Weissmann; F Dicker; A Kohlmann; S Schindela; W Kern; T Haferlach; S Schnittger
Journal: Leukemia Date: 2013-09-23 Impact factor: 11.528

7. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors: Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal: J Mol Diagn Date: 2015-03-20 Impact factor: 5.568

8. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.

Authors: Luciana Teofili; Fiorina Giona; Maurizio Martini; Tonia Cenci; Francesco Guidi; Lorenza Torti; Giovanna Palumbo; Angela Amendola; Giuseppe Leone; Robin Foà; Luigi M Larocca
Journal: Blood Date: 2007-07-20 Impact factor: 22.113

9. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

Authors: Sidong Huang; Michael Hölzel; Theo Knijnenburg; Andreas Schlicker; Paul Roepman; Ultan McDermott; Mathew Garnett; Wipawadee Grernrum; Chong Sun; Anirudh Prahallad; Floris H Groenendijk; Lorenza Mittempergher; Wouter Nijkamp; Jacques Neefjes; Ramon Salazar; Peter Ten Dijke; Hidetaka Uramoto; Fumihiro Tanaka; Roderick L Beijersbergen; Lodewyk F A Wessels; René Bernards
Journal: Cell Date: 2012-11-21 Impact factor: 41.582

10. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.

Authors: Kati Kämpjärvi; Tiina M Järvinen; Tuomas Heikkinen; Amy S Ruppert; Leigha Senter; Kevin W Hoag; Olli Dufva; Mika Kontro; Laura Rassenti; Erin Hertlein; Thomas J Kipps; Kimmo Porkka; John C Byrd; Albert de la Chapelle; Pia Vahteristo
Journal: Oncotarget Date: 2015-01-30

10 in total

1. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Authors: Roni Tamari; Franck Rapaport; Nan Zhang; Caroline McNamara; Andrew Kuykendall; David A Sallman; Rami Komrokji; Andrea Arruda; Vesna Najfeld; Lonette Sandy; Juan Medina; Rivka Litvin; Christopher A Famulare; Minal A Patel; Molly Maloy; Hugo Castro-Malaspina; Sergio A Giralt; Rona S Weinberg; John O Mascarenhas; Ruben Mesa; Damiano Rondelli; Amylou C Dueck; Ross L Levine; Vikas Gupta; Ronald Hoffman; Raajit K Rampal
Journal: Biol Blood Marrow Transplant Date: 2019-01-06 Impact factor: 5.742

2. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors: Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal: Blood Adv Date: 2018-12-26

3. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Authors: Raajit K Rampal; John O Mascarenhas; Heidi E Kosiorek; Leah Price; Dmitriy Berenzon; Elizabeth Hexner; Camille N Abboud; Marina Kremyanskaya; Rona Singer Weinberg; Mohamed E Salama; Kamal Menghrajani; Vesna Najfeld; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Judith D Goldberg; Ronald Hoffman
Journal: Blood Adv Date: 2018-12-26

Review 4. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

Authors: Jeffrey Patterson-Fortin; Alison R Moliterno
Journal: Curr Hematol Malig Rep Date: 2017-10 Impact factor: 3.952

5. Genomic characterization of spleens in patients with myelofibrosis.

Authors: Eran Zimran; Joseph Tripodi; Raajit Rampal; Franck Rappoport; Sharon Zirkiev; Ronald Hoffman; Vesna Najfeld
Journal: Haematologica Date: 2018-05-10 Impact factor: 9.941

6. CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.

Authors: Mariam T Nawas; Jeong-Ok Lee; Jessica Flynn; Molly Maloy; Ann A Jakubowski; Esperanza B Papadopoulos; Christina Cho; Doris M Ponce; Craig S Sauter; Miguel-Angel Perales; Sean Devlin; Sergio A Giralt; Hugo R Castro-Malaspina; Roni Tamari
Journal: Bone Marrow Transplant Date: 2022-04-28 Impact factor: 5.174

7. Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies.

Authors: Elizabeth A Comen; Robert L Bowman; Pier Selenica; Maria Kleppe; Noushin R Farnoud; Fresia Pareja; Britta Weigelt; Corinne E Hill; Abigail Alon; Felipe C Geyer; Guray Akturk; Jorge S Reis-Filho; Larry Norton; Ross L Levine
Journal: J Natl Cancer Inst Date: 2020-01-01 Impact factor: 13.506